Update, November 2, 2026. FDA extended the comment period to July 30, 2026 in a notice published June 26. We found no final decision as of this date, so this remains a proposal.
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. The agency said it “did not identify a clinical need” for outsourcing facilities to compound these drugs from bulk substances.
What changed. Outsourcing facilities, the larger compounders regulated under section 503B, generally may compound from bulk powder only if the substance is on the 503B bulks list or the drug is on FDA’s shortage list. The three GLP-1 drugs had been nominated for that list. The FDA has now proposed saying no. It invited public comments through June 29, 2026 and said it will consider them before a final decision.
What it means. If finalized, the decision would close the bulks-list route for 503B facilities to make these drugs while approved versions are available. FDA Commissioner Marty Makary said outsourcing facilities “cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”
If you take this or are considering it. If you use a brand-name pen, vial or pill, this proposal does not touch your supply. If you use a compounded GLP-1, the first thing to find out is who made it, because the proposal concerns outsourcing facilities and leaves the 503A pharmacy rules to a separate track. Your pharmacy can tell you which kind it is. Then ask your prescriber what the plan would be if that product stopped being available, and what an approved option would cost you. Nothing changes the day a proposal appears, and FDA has said comments will shape its final determination, so there is time to have that conversation.
What has not changed. This is a proposal, not a final decision. It does not affect the approved brand-name products, which remain available by prescription. The separate rules for 503A pharmacies are covered in the compounded tirzepatide guide and the FDA status tracker.